Resistant Infections: Superbugs and No Superdrugs
|
|
- Victor Elliott
- 6 years ago
- Views:
Transcription
1 Resistant Infections: To the SNF and Back Elizabeth Hudson, DO, MPH Department of Infectious Diseases Panorama City 9/15/12 Superbugs and No Superdrugs Antibiotics are often taken for granted Changes over time Value to society at low price Unique status > decreased development
2 Priority Antibiotic Pathogens ESKAPE bugs: Enterococcus faecium/faecalis (VRE), Staphylococcus aureus (MRSA, VISA, VRSA), Klebsiella species (ESBL, Carbapenamase producer), Acinetobacter baumannii (multi drug resistant) Pseudomonas aeruginosa (multi drug resistant) Enterobacter species (multi drug resistant) Clostridium difficile Vancomycin Resistant Enterococci (VRE) VRE: resistance from changing some cell wall proteins > decreased vanco binding vana gene seen in VRSA as well from VRE VRE first in Europe in the 80s use of antibiotic to increase animal weight VRE is now endemic in many major hospitals in the US Biggest risk factor for acquiring VRE is previous Vanco and cephalosporins Can lead to bowel colonization with VRE
3 VRE: Clinical Manifestations VRE can lead to: Bacteremia Urinary tract infections Meningitis Endocarditis Clinically Important VRE Types Vancomycin resistant E. faecalis Easier to treat Vancomycin resistant E. faecium Have concurrent high level resistance to beta lactams and aminoglycosides
4 VRE Treatment Base on in vitro susceptibilities Ampicillin (+/ sulbactam) (if Amp sensi) plus gentamicin or streptomycin E. faecalis: Linezolid, Synercid, Tigecycline, Daptomycin E. faecium: Synercid, Linezolid, Tigecycline, possibly high dose Daptomycin MRSA Methicillin resistant Staphylococcus aureus (MRSA) was described in 1961 Methicillin resistance is mediated by PBP 2a, a penicillin binding protein encoded by the meca gene Originally from CoNS gives resistance to PCN, Cephalosporins The meca gene is located on a mobile genetic element called staphylococcal chromosome cassette (SCCmec) >new strains!
5 MRSA Health Care Associated (HA MRSA): severe, invasive disease in hospitalized patients strains tend to have multidrug resistance and carry SCCmec type II Community Acquired (CA MRSA): young, healthy individuals with no recent health care exposure Usually causes skin and soft tissue infections carry SCCmec type IV or V and for cytotoxin Panton Valentine leukocidin (PVL) Increased virulence MRSA Manifestations MRSA can lead to: Bacteremia Endocarditis Osteomyelitis Pneumonia Severe skin and soft tissue infections
6 MRSA Lab Detection The most accurate methods to detect MRSA are: polymerase chain reaction (PCR) for detection of the meca gene and latex agglutination tests for the protein product of meca, penicillin binding protein 2a Traditional microbiology laboratory techniques Rapid testing > evolving area MRSA Treatments For invasive disease, IV therapy is needed Vancomycin Most experience Need to monitor levels Daptomycin: MRSA bacteremia, L sided endocarditis, csssi Monitor CK level Not for MRSA pneumonia (pulm surfactant inhibits)
7 MRSA Treatments Linezolid: Approved for MRSA pneumonia and csssi Toxicities and interactions limit use Static drug Tigecycline: Approved for csssi in MRSA Increased mortality risk Quinupristin dalfopristin(synercid): Approved for csssi; used if vanco fails Need central line to give Myalgias, hyperbili CA MRSA Treatment Usually these cause SSSI Can use oral antibiotics: Bactrim DS (2 DS BID for 14 days) Linezolid (600 mg Q12) Doxycycline Clindamycin: watch out if erythromycin resistant and clinda sensi Check D test for inducible resistance flattening of the clindamycin zone adjacent to the erythromycin disk (a "D zone"), indicates resistance
8 VISA (no, not the credit card!) VISA and hvisa: Staph aureus with a reduced susceptibility to vancomycin unusually thickened cell wall capable of binding vancomycin See in patients on dialysis or with MRSA bacteremia related to CVC or prosthetic graft material, and prolonged vancomycin exposure VRSA VRSA: vancomycin resistance via plasmidmediated transfer of the vana gene cluster from VRE 7 cases in US since 2002 (most in MI) Chronically ill people 100% mortality after 6 months:? If VRSA cause
9 Treatment VISA/VRSA Best treatment of VRSA/VISA is unknown Lab testing shows most of these isolates are also usually susceptible to the daptomycin, linezolid, and quinupristin dalfopristin Increasing the dose of vancomycin not helpful Quinolones should not be used even if susceptible by lab > resistance develops quickly Extended spectrum beta lactamases (ESBL) producing Enterobacteriaceae Beta lactamases are enzymes that open the beta lactam ring, inactivating the antibiotic ESBLs are enzymes that confer resistance to most beta lactam antibiotics (e.g. PCN, cephalosporins, and aztreonam) ESBLs have been found exclusively in Gram negative organisms, primarily in: Klebsiella pneumoniae, K.oxytoca, and Escherichia coli Seen less in Acinetobacter, Burkholderia, Citrobacter, Enterobacter, Morganella, Proteus, Pseudomonas, Salmonella, Serratia, and Shigella spp.
10 ESBL There are multiple types of ESBLs TEM, SHV, CTX M, OXA Identification of ESBLs is lab dependent and cumbersome for the best labs One clue organism is sensitive to some 2nd generation cephalosporins (e.g. cefoxitin, cefotetan), but resistant to third generation cephalosporins Risk factors for acquisition similar to those of other superbugs : Length of hospital stay Presence of central venous or arterial catheters Gut colonization (may be reservoir) Prior administration of any antibiotic SNF resident Undergoing hemodialysis ESBL Treatment The only current proven therapeutic option for severe infections caused by ESBLproducing organisms is the carbapenem family: Imipenem: increased risk of seizures Meropenem Ertapenem (does not cover Pseudomonas)
11 Carbapenamases and Gram Negatives Carbapenamases are carbapenem hydrolyzing beta lactamases that confer carbapenem resistance Various classes including A, B C, and D First seen in the early 1990s in NE US and now throughout the world Carbapenamase A: KPC group Most clinically important of the Class A Carbapenamases is the KPC (Klebsiella pneumoniae carbapenemase) group These enzymes reside on a transmissible plasmid and confer resistance to all beta lactams KPC can be transmitted from Klebsiella to other genera, including E. coli, Pseudomonas aeruginosa, Citrobacter, Salmonella, Serratia, and Enterobacter spp
12 Carbapenamase A: KPC group Many KPC producing organisms have Imipenem or Meropenem MICs that remain in the susceptible range: look for Imi/Mero MICs are very high Recovery of an isolate that is susceptible to third generation cephalosporins but resistant to Imipenem Carbapenamase A: KPC group To improve detection can: Use Ertapenem to check susceptibility for all types of bacteria Modified Hodge test (only for E coli and K pneumo) This test involves streaking a clinical isolate near an Imipenem disk that has been placed on an agar plate containing a susceptible control organism Growth of the control organism around the Imipenem disk in the region of the streak suggests carbapenemase activity in the clinical isolate
13 Treatment for Carbapenamase Producers The optimal treatment of infection due to carbapenemase producing organisms is uncertain, and antibiotic options are limited Drugs that have been successful are: Tigecycline, Colistin, and Aztreonam Acinetobacter spp. Acinetobacter spp has been traditionally classified as an opportunistic pathogen of relatively low pathogenicity Known to cause nosocomial infections SNF patients, ICU patients Emergence of community acquired Acinetobacter infections highly virulent with a propensity to cause invasive disease in non critically ill patients
14 Acinetobacter spp. Hardy, can stay in environment and on people for a long time Colonizes ~ 10 % of HCWs Can see many different kinds of infections Bloodstream VAP UTIs Endocarditis Meningitis Acinetobacter species are innately resistant to many classes of antibiotics, including penicillin and often aminoglycosides Try Carbapenems and Colistin Clostridium difficile (C. difficile) Antibiotic associated diarrhea and colitis were well established soon after widespread use of antibiotics In 1978, C. difficile was identified as the causative pathogen in the majority of cases, Attributed largely to clindamycin then later to cephalosporins as use increases
15 Clostridium difficile (C. difficile) From 2003 to 2006, C. difficile infections were observed to be more frequent, more severe, more refractory to standard therapy, and more likely to relapse than previously described Attributed to a new strain designated BI, NAP1 Fluoroquinolone use has strongly correlated with the emergence of this strain Seeing more community associated infection since late 2000s More colonization/asymptomatic carriers C diff Epidemiology Dramatic increases in the incidence and severity of healthcare associated C. difficile infection have occurred over since 2000, particularly in patients over age 65 Rate of nosocomial C. difficile associated diarrhea (CDAD) in the US doubled from 31 per 100,000 to 61 per 100,000 between 1996 and 2003 C. difficile carriage occurs in 20 to 50 percent of adults in hospitals and long term care facilities (3% in healthy people) About 20 percent of patients with negative admission stool cultures become infected during their hospitalization. Asymptomatic can act as reservoir of illness for others.
16 Risk Factors for C diff Antibiotic use: how? Disrupt normal colonic flora, providing a niche for C. difficile to multiply and elaborate toxins. In a small series of patients with CDAD, for example, absence of Bacteroides species (a predominant species in normal colonic flora) was noted during CDAD but returned following resolution of symptoms Development of C. difficile antibiotic resistance to clindamycin or fluoroquinolones appears to play an important role in disease due to strains with increased virulence Risk Factors for C diff Perioperative antibiotic prophylaxis also confers risk for C difficile Think: Does pt really need IE prophlyaxsis for a procedure? Advanced Age PPI use: controversy
17 Clinical Manifestations Carrier state : reservoir Diarrhea with colitis Manifestations of C. difficile associated diarrhea with colitis include watery diarrhea up to 10 or 15 times daily with lower abdominal pain and cramping, Low grade fever, and Leukocytosis: usually quite elevated (e.g. >20K) Unexplained leukocytosis in hospitalized patients (even in the absence of diarrhea) may reflect underlying C. difficile infection Pseudomembranous colitis : sigmoidoscopic examination in these patients demonstrates the presence of pseudomembranes, which is sufficient to make a presumptive diagnosis of C. difficile infection Clinical Manifestations Fulminant colitis: severe lower quadrant or diffuse abdominal pain, diarrhea, abdominal distention, High fever, hypovolemia, lactic acidosis, and marked leukocytosis (e.g. 40 K or higher) Toxic megacolon is a clinical diagnosis based upon the finding of colonic dilatation (>7 cm in its greatest diameter) accompanied by severe systemic toxicity Check ARX Watch for perforation Aggressive diagnostic and therapeutic interventions are warranted in the setting of fulminant C. difficile infection: Medical and sometimes surgical therapy needed
18 Diagnosis Clinical diagnosis; don t wait for lab confirmation in right clinical scenario! Kaiser So Cal uses real time PCR: rapid and accurate Depending on when sample to lab get results back within 24 hours. So sensitive that once done, do not recommend rechecking C diff for 2 weeks unless extenuating circumstances Colonoscopy or sigmoidoscopy can be a useful adjunctive tool for diagnosis of C. difficile in the following settings: High clinical suspicion for C. difficile with negative laboratory assay(s) Prompt C. difficile diagnosis needed before laboratory results can be obtained Failure of C. difficile infection to respond to antibiotic therapy Atypical presentation with ileus or minimal diarrhea Treatment of C diff: Non Severe Oral Flagyl or Oral Vancomycin Is one better than the other? Not clear from studies Dosage: Flagyl: 500 mg PO three times daily or 250 mg four times daily for 10 to 14 days. Vanco: 125 mg PO four times daily. Patients with an underlying infection requiring prolonged duration of antibiotics should continue CDIAD treatment throughout the antibiotic course plus one additional week after its completion Repeat stool assays are NOT warranted during or following treatment in patients who are recovering or are symptom free.
19 Treatment of C diff: Severe Disease There is no consensus definition for severe CDI, nor is there agreement as to the most important clinical indicators that should be used to differentiate severity Patients with acute C. difficile infection (CDI) may develop signs of systemic toxicity with or without profuse diarrhea warranting admission to an intensive care unit or emergency surgery Treatment of C diff: Severe Disease First line therapy: PO Vanco: 125 mg 500 mg Dose depends on severity of illness and clinician choice If no better with PO Vanco, can consider Fidaxomicin (new Macrolide drug just for C diff; absorbed locally only) Adding IV Flagyl may be helpful in severely ill patients with ileus Intracolonic Vanco Surgery: last resort!
20 Treatment of Recurrent C diff Management of initial recurrence: confirm clinically mild symptoms of recurrence who are otherwise well may be managed conservatively, without further antibiotic therapy Non severe initial recurrence following therapy for CDI can be treated with Flagyl, 500 mg PO Q 8 for days Vanco can be used, too, but would reserve for sicker patients C diff back again and again what to do? Tapering dose of vancomycin Rifaximin chaser Fidaxomicin Stool transplant
21 Beware the Clostridiapocalypse! Movie clip to come
Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationMulti-Drug Resistant Organisms (MDRO)
Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationHealthcare-associated Infections Annual Report December 2018
December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationBeta-lactam antibiotics - Cephalosporins
Beta-lactam antibiotics - Cephalosporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability ypropertiesp Stability to bacterial
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationCarbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S
Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationCell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification
Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationClostridium difficile Colitis
Update on Clostridium difficile Colitis Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA
More informationUsing Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and
Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Health-Care Associated Infections Overall Goals & Objectives:
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationCa-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007
Ca-MRSA Update- Hand Infections Washington Hand Society September 19, 2007 Resistant Staph. Aureus Late 1940 s -50% S.Aureus resistant to PCN 1957-80/81 strain- of S.A. highly virulent and easily transmissible
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationTaking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms
Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationLEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES
LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationInfection Control & Prevention
Infection Control & Prevention Objectives: Define the term multi-drug resistant organism (MDRO). Recognize risk factors for developing MDROs. Describe the clinical manifestations and medical treatment
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationMicrobiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:
Microbiology Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention June 2017 MeshHp (VS) Medical Care Center Dr. Eberhard & Partner Dortmund (ÜBAG) www.labmed.de MVZ Dr. Eberhard &
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationOverview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases
Overview of C. difficile infections Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases Conflicts of Interest I have no financial conflicts of interest related to this topic and presentation.
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationAntibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship
Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationOrigins of Resistance and Resistance Transfer: Food-Producing Animals.
Origins of Resistance and Resistance Transfer: Food-Producing Animals. Chris Teale, AHVLA. Origins of Resistance. Mutation Brachyspira hyodysenteriae and macrolide and pleuromutilin resistance. Campylobacter
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationAntibiotic Resistances Profile in Iran, Clinical Implication and Prospect for Antibiotic Stewardship Jafar Soltani
Antibiotic Resistances Profile in Iran, Clinical Implication and Prospect for Antibiotic Stewardship Jafar Soltani Pediatrics Department, Faculty of Medicine, Kurdistan University of Medical Sciences,
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationMethicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus By Karla Givens Means of Transmission and Usual Reservoirs Staphylococcus aureus is part of normal flora and can be found on the skin and in the noses of one
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More information